<code id='0B603EB61E'></code><style id='0B603EB61E'></style>
    • <acronym id='0B603EB61E'></acronym>
      <center id='0B603EB61E'><center id='0B603EB61E'><tfoot id='0B603EB61E'></tfoot></center><abbr id='0B603EB61E'><dir id='0B603EB61E'><tfoot id='0B603EB61E'></tfoot><noframes id='0B603EB61E'>

    • <optgroup id='0B603EB61E'><strike id='0B603EB61E'><sup id='0B603EB61E'></sup></strike><code id='0B603EB61E'></code></optgroup>
        1. <b id='0B603EB61E'><label id='0B603EB61E'><select id='0B603EB61E'><dt id='0B603EB61E'><span id='0B603EB61E'></span></dt></select></label></b><u id='0B603EB61E'></u>
          <i id='0B603EB61E'><strike id='0B603EB61E'><tt id='0B603EB61E'><pre id='0B603EB61E'></pre></tt></strike></i>

          
          WSS
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          comprehensive